General Information of DTT (ID: TTNVXAW)

DTT Name Lymphocyte activation gene 3 protein (LAG3) DTT Info
Gene Name LAG3

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
1 Approved Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Relatlimab DM28AZV Melanoma 2C30 Approved [1]
------------------------------------------------------------------------------------
15 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Anti-LAG3 DMJO402 Gastric adenocarcinoma 2B72 Phase 2 [2]
BMS-986016 DMDCHM7 Hematologic tumour 2B33.Y Phase 1/2 [3]
Favezelimab DMYAIE2 Non-hodgkin lymphoma 2B33.5 Phase 1/2 [4]
IMP-321 DM18ZLW Allergy 4A80-4A85 Phase 1/2 [5]
A289 DMO4DSH Aggressive cancer 2A00-2F9Z Phase 1 [6]
ADPT01 DMS6DPF Breast cancer 2C60-2C65 Phase 1 [7]
FS118 DM0QH9K Advanced cancer 2A00-2F9Z Phase 1 [8]
GSK2831781 DMC47M9 Autoimmune disease 4A40-4A45 Phase 1 [9]
GSK4074386 DMI3FU6 Solid tumour/cancer 2A00-2F9Z Phase 1 [10]
IMP-701 DMXSMF9 Solid tumour/cancer 2A00-2F9Z Phase 1 [11]
INCAGN2385 DMDSZNC Melanoma 2C30 Phase 1 [12]
MK-4280 DMCA1NX Neoplasm 2A00-2F9Z Phase 1 [13]
RG6139 DMJFM3O Solid tumour/cancer 2A00-2F9Z Phase 1 [14]
Sym022 DMCK2YR Lymphoma 2A80-2A86 Phase 1 [15]
XmAb22841 DMQB3HD Solid tumour/cancer 2A00-2F9Z Phase 1 [16]
------------------------------------------------------------------------------------
⏷ Show the Full List of 15 Clinical Trial Drug(s)
2 Investigative Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Concatameric LAG3Ig DMRPV0A Discovery agent N.A. Investigative [11]
IMP-731 DM1TQXO Autoimmune diabetes 5A10 Investigative [11]
------------------------------------------------------------------------------------
Molecule Interaction Atlas

References

1 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761234
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol. 2015 March; 7(2): 85-96.
4 A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer. ESMO Open. 2022 Dec;7(6):100639.
5 A soluble form of lymphocyte activation gene-3 (IMP321) induces activation of a large range of human effector cytotoxic cells. J Immunol. 2007 Sep 15;179(6):4202-11.
6 Clinical pipeline report, company report or official report of Klus Pharma
7 Clinical pipeline report, company report or official report of Novartis.
8 Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
9 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10 Clinical pipeline report, company report or official report of GlaxoSmithKline.
11 IMP321 (sLAG-3), an immunopotentiator for T cell responses against a HBsAg antigen in healthy adults: a single blind randomised controlled phase I study. J Immune Based Ther Vaccines. 2007 Mar 29;5:5.
12 Clinical pipeline report, company report or official report of Agenus.
13 Establishment of engineered cell-based assays mediating LAG3 and PD1 immune suppression enables potency measurement of blocking antibodies and assessment of signal transduction. J Immunol Methods. 2018 May;456:7-14.
14 Clinical pipeline report, company report or official report of Genentech.
15 Clinical pipeline report, company report or official report of Symphogen.
16 Clinical pipeline report, company report or official report of Xencor.